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Background: There is no valid and reliable instrument to evaluate genetic education and counseling received by parents who have an infant with a
positive newborn screen for cystic ﬁbrosis (CF).
Methods: This study assessed the validity and reliability of a new instrument designed to evaluate the effectiveness of genetic education and counseling
received by parents who have an infant with a positive newborn screen for cystic ﬁbrosis (CF). A 16-item CF genetic knowledge questionnaire
(CFGKQ) was completed by 84 members of the general population (GP) and 441 genetic counselors in the United States. Participants also rated the
importance of genetic content.
Results: Signiﬁcant group differences were found in mean percentages of correct responses (pb0.05). High consistency was found between initial and
follow-up questionnaire administrations. Cronbach's alpha scores=0.82–0.85 initially and 0.77–0.81 at follow-up administrations. Two items lacking
empirical support were removed. In comparison to genetic counselors, GP respondents placed greater importance on recurrence risks and implications
of a CF diagnosis for family members than the newborn screening process or autosomal recessive mechanisms.
Conclusions: The 14-item CFGKQ appears to have promising validity and reliability for use within the United States. This instrument may be a useful
tool in the development of evidence-based genetic education and counseling programs. Additional research is needed to validate this instrument for use
with other populations.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Genetic knowledge; Newborn screening1. Introduction
Newborn screening (NBS) for cystic fibrosis (CF) has been
initiated throughout Australasia, North America, most European
countries, and parts of South America [1]. Most protocols include
some combination of immunoreactive trypsinogen (IRT) mea-
surement and DNA analysis [1–3]. When infants are found to
have an elevated IRT level plus one or more mutations in the
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http://dx.doi.org/10.1016/j.jcf.2012.12.001gene, families are referred for diagnostic sweat testing. Although
NBS is designed to identify pre-symptomatic infants with CF,
inclusion of DNA analysis incidentally detects heterozygote CF
carriers not expected to develop CF symptoms. Such genetic
findings have reproductive implications for the child in the future,
the infant's parents, and other family members. Consequently,
provision of genetic counseling during sweat test appointments is
recommended [4].
Such counseling is often complicated by parental stress,
anxiety, or depressive symptoms [5,6]. Research also shows,
even with genetic counseling, many parents remain confused
about the implications of their infant's carrier status [7], the
limitations of carrier testing [8,9], and their chances of having a
future child with CF [10]. The complexity of genetics [11,12]by Elsevier B.V. All rights reserved.
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the challenges of educating parents during the NBS process.
Standardized, empirically-valid, and reliable instruments are
essential to evaluate the effectiveness of clinical practices and to
develop evidence-based genetic educational interventions for
parents of infants with abnormal NBS results for CF. Without
such measures, it is difficult to draw accurate conclusions about
whether parent-reported knowledge, or lack thereof, is due to the
clinician's approach or the limitations of the instrument. Previous
studies have produced valid questionnaires for use in particular
study populations or study sites [14–16]. However, none have
been validated for use in individuals of child-bearing age within
the general population of the United States. Thus, this study
expands the repertoire of available instruments to include one
specifically designed to address the increasing need to evaluate the
effectiveness of genetic counseling associated with NBS for CF.
1.1. Parent information preferences
Research has emphasized the educational aspect of genetic
counseling [17,18]. To our knowledge, only one study explored
parent preferences about the content of such educational
information. Findings suggested that counseling matched to
parents' preferences reduced parents' distress and genetics was
identified as a preferred topic [19]. However, no studies to date
have examined which aspects of genetics parents view as most
important.
1.2. Cystic fibrosis knowledge questionnaires
Several CF knowledge questionnaires designed to assess
patient knowledge of CF genetics related to reproductive risks
have been developed in the United States (US) [20], Austria [21],
Italy [22], South Africa [15], Canada [23], and the United
Kingdom [24,25]. However, these questionnaires were devel-
oped for particular study sites or were not standardized. Genetic
knowledge was typically only one aspect of the instruments
which mainly focused on disease-specific symptoms and related
health management. A 40-item CF knowledge questionnaire,
validated solely for use with adult CF patients in Ireland, includes
nine genetics questions [14]. Two questionnaires assess parent
knowledge of CF emphasizing reproductive decisions and
behaviors [26,27]. These instruments do not address recurrence
risks and CF genetics and/or lack empirical validation. Few
instruments [8,9] address parent knowledge of the limitations of
CF carrier testing. None were developed and empirically
validated to evaluate CF genetic knowledge in individuals of
child-bearing age within general populations, and, thus, are not
applicable for use in studies with parents of newborns likely to
undergo genetic counseling following abnormal NBS results for
CF.
The two-fold purpose of this study was (1) to develop and
evaluate the psychometric properties of a cystic fibrosis genetic
knowledge questionnaire (CFGKQ) for use in research and
clinical practice and (2) to compare the perceived importance of
genetic content reported by genetic counselors and adults in the
general population.2. Methods
This de novo instrument development study employed a
crossover design that was approved by the Health Sciences
Institutional Review Board at University of Wisconsin-Madison.
All subjects gave informed consent to participate.
2.1. Participants
The sample was recruited from two populations: one with
specialized genetic knowledge and one without such knowledge.
Master's prepared genetic counselors who are members of the
National Society of Genetic Counselors (NSGC group) were
expected to correctly answer most items. They were recruited
through the NSGC on-line list serve. Members of the general
population (GP group) were considered less likely to possess
specialized genetic knowledge to correctly answer most items.
They also are representative of most parents likely to receive
genetic counseling following abnormal CF NBS results. Based
on our previous research [28], the GP inclusion criteria required
participants to be between ages 18 and 50 years. They were
recruited through the “volunteers” option on a nationwide,
on-line community social network. Given that our aim was to
create an instrument that would assess new genetic knowledge
likely to be learned through genetic counseling, we systemati-
cally excluded from the GP group anyone whomight have gained
such specialized knowledge prior to participating in this study.
Therefore, individuals were not eligible for participation in the
GP group if they had CF or relatives with CF, received genetic
counseling for CF, had college level genetics coursework, or
were health care providers. Both groups were recruited from all
regions of the continental US.
2.2. Questionnaire development
Sixty-two genetic counseling topics were identified through
literature review and information obtained from our previous
research of genetic counseling sessions associated with NBS for
CF [29]. Using a modified nominal process [30], twelvemembers
of the NSGC Special Interest Group (SIG) for CF used
Likert-type scales to rate these concepts in relation to (a) the
frequency in which topics are addressed during counseling
sessions (1=only if parents ask to 3= topic always discussed) and
(b) the importance of parents understanding and retaining the
information (1=not important to 5=very important). Genetic
counselors were also invited to list additional content not
included in this initial survey. From these responses, 30 items
with mean rankings ≥4.0 for frequency and importance were
developed into a 20-item instrument [31]. This version was
reviewed by four content experts (three genetic counselors with
expertise in CF and the director of a genetic counseling graduate
program) for content validity and item construction. A survey
construction expert also reviewed and offered recommendations
about format, verbiage, and response choices. Three individuals
from the general population with no science background
reviewed the questionnaire for readability. Consequently, four
questions were removed and minor edits were made.
Table 1
Participant demographic characteristics.
Characteristic NSGC
N=441
GP
N=84
Gender % %
Female 95 25
Male 4 74
Other b1 1
Age
18–20 0 12
21–30 47 46
31–40 34 21
41–50 15 21
Over 50 4 0
Education
Middle school completed (Grades 7–8) 0 1
High school or GED completed (Grades 9–12) 0 32
Associate's degree completed 0 13
Bachelor's degree completed 0 32
Graduate degree(s) completed 100 21
Race/ethnicity
African American (Black) b1 10
Asian American 3 13
European American (White) 92 60
Hispanic b1 5
Native American (American Indian) 0 1
Pacific Island American 0 1
Mixed b1 4
Other 3 6
Parental status
Parent 38 23
Not a parent 62 77
*NSGC CF SIG member (NSGC only)
Yes 4 N/A
No 96 N/A
N/A=not applicable.
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directive items that assess knowledge of CF genetics (autosomal
recessive nature, recurrence risks, limitations of carrier testing)
using five multiple-choice and 11 true–false questions. Response
options for multiple choice items were based on the literature
[8,14–16,22,23,32,33] which resulted in variable numbers of
answers for these items. Five-point Likert-type scales, referred to
as “importance items” (1=not at all important, 5=extremely
important), measured respondents' perceptions about the impor-
tance of content associated with each item. GP participants were
asked to rate the importance of the items as if they had a child
with an abnormal NBS for CF. NSGC participants were asked to
rate how important they believe it is for parents of infants with
abnormal NBS for CF to understand and retain the content of
each item. Finally, we created a demographic form with six
questions (age, gender, whether participant is a parent, education
level, race/ethnicity, and, membership in CF SIG—for NSGC
group only). All three components of data collection took
approximately 5–10 min to complete.
2.3. Data collection
Questionnaires were distributed via the national on-line
survey software, Qualtrics. Participants were instructed to enter
a valid email address and complete an initial and two-week
follow-up questionnaire only once. The two week interval
between completions was chosen to evaluate test–retest reliabil-
ity [16,34]. To examine whether the importance items posed a
confound to responses, we designed two questionnaire forms:
one with importance items (Form A) and one without (Form B).
Using a crossover design, participants randomly received either
form initially and the opposite form at the two-week follow-up. A
minimum of 75% (12 questions) completion was required for
response to be included in the data analysis. Entry into a lottery
drawing for a new iPad was offered as incentive for completing
the initial and follow-up survey.
2.4. Analytic procedures
2.4.1. Validity
Content validity, the degree to which items adequately
represent the domain of interest [31], was established through
CF genetics expert evaluation. Face validity, the transparency of
topic measured, was confirmed through review by professionals
and members of the general population. Construct validity, extent
to which the instrument measures what it aims to measure, was
established by disseminating the instrument to two groups of
individuals who were expected to differ in levels of content
knowledge. To minimize threats to validity caused by guessing, a
“not sure” response option was included for each item.
2.4.2. Reliability
To evaluate the consistency of the instrument over time, an
assessment of test–retest item reliability was performed [34].
Perreault and Leigh's index of reliability (Ir) [35] was used to
compare the differences between initial and follow-up admin-
istrations, with 95% confidence intervals for item correctness[36,37]. Overall test–retest reliability was then assessed by the
Spearman correlation and average index of reliability. Group
differences in the proportion of correct responses were assessed
using the difference of two binomial proportions of unconditional
95% confidence intervals [38]. Additionally, overall instrument
and individual item Cronbach's alpha scores were calculated for
the initial and follow-up administrations.
2.4.3. Importance items
Mean difference in item importance was calculated using the
standardized mean difference (Cohen's d-family statistic) [39].
3. Results
3.1. Participant demographics
Table 1 summarizes demographic information for the 525
participants who completed the questionnaire.
3.2. Confounding assessment
Assessment of the potential confounding influence of impor-
tance items on knowledge items, e.g., bias due to simultaneous
presentation of importance and knowledge items, was handled by
Table 2
Index of reliability for observed agreement correct between initial and follow-up
questionnaire administrations.
Item NSGC
Ir (confidence intervals)
GP
Ir (confidence intervals)
1 0.952 (0.929, 0.975) 0.700 (0.579, 0.821)
2 0.987 (0.975, 0.999) 0.404 (0.274, 0.534)
3 0.990 (0.980, 1.00) 0.447 (0.315, 0.578)
4 0.993 (0.985, 1.00) 0.774 (0.664, 0.885)
5 0.952 (0.929, 0.975) 0.797 (0.691, 0.903)
6 0.942 (0.917, 0.968) 0.629 (0.499, 0.759)
7 0.996 (0.990, 1.00) 0.816 (0.713, 0.919)
8 0.981 (0.966, 0.996) 0.808 (0.701, 0.915)
9 0.993 (0.985, 1.00) 0.629 (0.499, 0.759)
10 0.807 (0.764, 0.850) 0.764 (0.650, 0.878)
11 0.996 (0.990, 1.00) 0.658 (0.531, 0.786)
12 0.984 (0.971, 0.997) 0.509 (0.375, 0.642)
13 0.996 (0.990, 1.00) 0.774 (0.664, 0.885)
14 0.935 (0.908, 0.962) 0.700 (0.579, 0.821)
15 0.993 (0.985, 1.00) 0.720 (0.600, 0.839)
16 0.823 (0.781, 0.865) 0.745 (0.629, 0.861)
Mean Ir
a 0.978 0.679
Spearman's rho 0.425 (0.288, 0.545) 0.709 (0.388, 0.876)
Ir= index of reliability.
a Excludes items #10 and #16.
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knowledge and importance was evaluated by simple proportional
and mean contrasts, respectively. Differences are considered
indicative of confounding effects. Assessments at the item levels
and the overall score levels indicated no statistically significant
differences at pb0.05 level. Subsequently, no presentation
confounds were detected, and importance assessed at initial and
follow-up administrations were combined in the analysis.
3.3. Validity
Accuracy of responses between NSGC and GP group were
found to be significantly different for all 16 items of the CFGKQ
(Fig. 1). Questions #10 and #16, however, were shown to be
outliers. Only 45% ofNSGC and 20%ofGP participants answered
#10 correctly and 80% of NSGC and 20% of GP participants
answered #16 correctly (Fig. 1).
3.4. Reliability
Three hundred and eighty-two out of 525 (73%) participants
completed both administrations of the questionnaire as a measure
of test–retest reliability. Except for items #10 and #16, the index
of reliability (Ir) was strong for each item (Ir 0.942 to 0.996)
completed by the NSGC group and moderate to strong for the GP
group (Ir 0.404 to 0.816). The Ir results for both groups were less
reliable for items 10 (NSGC=0.807, GP=0.745) and 16
(NSGC=0.823, GP=0.764). Spearman's rho correlations ranged
from 0.425 for NSGC to 0.709 for GP (Table 2). However,
because the correlation score is greatly influenced by the
heterogeneity of the sample, the low variability of the NSGC
responses produced a lower correlation coefficient [40]. Thus, the
average Ir of 0.978 in NSGC group and 0.679 in GP group
between initial and follow-up administrations is a more accurate
reflection of the reliability which is strong. Overall instrument
Cronbach's alpha scores for initial and follow-up administrationFig. 1. Mean percent correct per CFGKQ item for NSGC and GP participants.were 0.80 and 0.85. Table 3 lists Cronbach's alpha scores and
item-total score correlations for individual items at initial and
follow-up administrations.
3.5. Cystic fibrosis genetic knowledge
Group differences between mean CFGKQ percentages of
correct scores for each item are illustrated in Figs. 1 and 2. As
expected, the NSGC group scored significantly higher than the
GP group on every item (Fig. 2) with over 90% correct for every
item, except for items #10 and #16. GP participants reported a
fairly good understanding that two individuals who are CF
carriers can have a healthy child without CF (62% correct) and
that siblings of a child who is a CF carrier can also be a carrier
(70% correct). The GP group had fewer correct responses on item
4which is the statistical chances, e.g., 25% or 1 in 4, of two carrier
parents having a child with CF (23% correct) and item 5 which is
the limitations of carrier testing for parents (12% correct). It is
noteworthy that items 4 and 5 also offered more answer options
than other items.
3.6. Importance
As shown in Fig. 3, the GP group rated items pertaining to
certain topics as significantly more important than ratings given
by the NSGC group. GP respondents placed higher importance
on knowledge of residual recurrence risk after negative carrier
testing (#5), family history of CF and carrier status (#7), carrier
status and illness (#9), carrier status of siblings of a CF carrier
(#13), and chance of future children being carriers (#15). The
NSGC group viewed information regarding the NBS process and
autosomal recessive mechanisms as more important (items #1,
#3, #11). There was no significant relationship between actually
Table 3
Reliability evaluation without items Q10 and Q16.
Initial administration Follow-up administration
Item # % Correct Alpha coefficients Item-total correlation % Correct Alpha coefficients Item-total correlation
1 52 0.84 0.37 60 0.81 0.15
2 33 0.84 0.39 63 0.80 0.26
3 41 0.84 0.44 63 0.78 0.52
4 16 0.85 0.18 23 0.79 0.29
5 14 0.86 0.10 12 0.80 0.11
6 31 0.84 0.51 52 0.78 0.42
7 26 0.84 0.48 37 0.77 0.55
8 25 0.84 0.41 35 0.79 0.29
9 40 0.83 0.66 63 0.77 0.60
11 55 0.82 0.71 67 0.78 0.52
12 40 0.83 0.61 52 0.78 0.50
13 62 0.82 0.69 77 0.77 0.59
14 58 0.83 0.60 77 0.79 0.40
15 40 0.83 0.58 48 0.77 0.60
Total 0.85 0.80
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on importance items.
4. Discussion
Various aspects of provider–patient communication related to
positive NBS results have been studied extensively [41–44].
However, this is the first study to develop a valid and reliable
instrument specifically designed to quantify the CF genetic
knowledge parents gain and retain as an outcome of such health
care encounters. This study is also the first to evaluate the
importance of specific genetic topics as perceived by individuals
in the general population in comparison with genetic counselors.
Our findings demonstrate that the 14-item CFGKQ appears to be
a valid and reliable tool for assessing genetic knowledge among
individuals in the US general population who are of child-bearingFig. 2. Group difference in percent correct. Boxes represent the average group differences i
percent correct. Differences in percent correct and confidence intervals that do not cross
scores bNSGC scores.age and have at least a high school education. Therefore, the
instrument may be useful in evaluating the outcomes of genetic
education/counseling programs. Although designed specifically
for the context of NBS, this instrument could potentially be used
in prenatal programs as well. With the advent of DNA analysis in
prenatal testing and NBS, evidence-based genetic counseling
practices are becoming increasingly important to the provision of
quality healthcare.
Two questions (#10 and #16) were removed due to their poor
psychometric properties. Question #10 asked whether being a
cystic fibrosis carrier could cause fertility problems. The correct
answer is “false.” This item was written based on previous
research that found misconceptions regarding this issue [28].
However, this question may have been misconstrued by readers
as asking whether having CF causes fertility problems which is
“true.” Question #16 addresses autosomal recessive inheritancen percent correct; lines represent the 95% confidence interval around the differences in
“0” are statistically significant at the pb0.05 level. Negative differences indicate GP
Fig. 3. Group difference in importance rating per item. Boxes represent the effect size
point; lines represent the 95% confidence interval around the effect size. Means and
confidence intervals that do not cross “0” are statistically significant at the pb0.05
level. Negative effect sizes indicate lower importance perceived by NSGC compared
to GP.
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carrier and the other is not. The placement of this question at the
end of the questionnaire could have contributed to incorrect
responses because participants might have misinterpreted the
question as inquiring about residual risk following negative
carrier testing. Placement of this question toward the beginning of
the questionnaire might have resulted in higher percentages of
correct answers.
The group differences found in importance ratings is
noteworthy. People in the general population rated information
about NBS process and the mechanics of genetics, e.g., that an
affected individual inherits a genetic change from each parent, as
less important information compared to the ratings from the
genetic counselors. Both groups rated the following topics as two
of the most important topics to know: reproductive recurrence
risks and the chance of having a healthy child in the future.
However, the groups differed in that the general population placed
more importance on what a diagnosis may mean for other family
members, including siblings of the affected child, and if carriers
may eventually develop illness. These findings lend further
support to the value of tailored, client-centered counseling to elicit
parents' preferences, concerns, and questions early in genetic
counseling sessions. By focusing on parents' principal concerns,
the counseling process may be more effective in helping parents
understand, assimilate, and make use of genetic information.
We wondered if participants who were parents might rate the
importance of individual items differently than non-parents.
Results revealed no significant differences between parents and
non-parents in regard to importance of items. This finding suggests
that parents and non-parents are (a) equally able to imagine a
situation in which they have an infant with an abnormal NBS for
CF and/or (b) value similar aspects of genetic information.This study has several limitations which should be considered.
All individuals from the general population were recruited from a
social networking website within the US, using non-random
convenience sampling. Almost all of the participants had at least a
high school education. This potential sample bias suggests that this
instrument be used with caution in those with less than a high
school education, limited English proficiency, or populations
outside the US. Replication of this study using recruitment from
other sources, in individuals with lower education, and populations
outside the US would strengthen the generalizability of the
instrument's applicability. Although steps were taken to encourage
participants to complete the initial and follow-up questionnaire
administration only once, the on-line survey software does not
ensure that individuals followed these instructions. However, we
believe that the likelihood of this occurring was small because no
duplicate emails were found and separate computers would have
been required for multiple submissions. Due to the homogeneity in
NSGC group scores, there was not a sufficient statistical test to
accurately portray the true reliability of the instrument. Thus, it is
likely that the Spearman rho's coefficients are underestimates of
the actual reliability. There also were notable differences in gender
between members of the GP and NSGC groups. Siklosi et al.
showed that female gender was associated with higher CF
knowledge scores among adults with CF [14]. While members of
the GP group were not adult CF patients, the male predominance
of the GP group could have influenced the level of correct answers.
Differences in the number of answer options could also have
affected the percent correct, particularly for items 4 and 5. Finally,
there were notable differences in the sample sizes of the NSGC and
general public groups. Still, the sample size afforded adequate
statistical power to address our research questions. Future research
is needed to address these methodological issues and determine the
appropriateness of using the instrument across clinical samples,
and populations outside the US.
5. Conclusions
The final 14-item CFGKQ appears to be a valid and reliable
instrument to assess knowledge of CF genetics in adult members
of the US general population. Although additional psychometric
work is warranted, it holds much promise as a valuable tool for
use in future research and clinical practice. In comparison with
genetic counselors, people in the general population seem to
place greater importance on learning the chances of having a
child with CF, consequences of a CF diagnosis for family
members, and health implication for CF carriers; while they place
less emphasis on the genetic mechanics of CF. These findings
lend further support to the value of tailored, client-centered
genetic counseling.
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Appendix A. CFGKQ*
Directions: Please select the best answer to each question
based on your knowledge of cystic fibrosis. If you are not sure
about an answer, you may mark “not sure.”
1. If an infant is found to have one defective cystic fibrosis
gene through newborn screening and no additional testing has
been done yet, which of the following statements is correct?
a. The infant definitely has cystic fibrosis
b. The infant is only a cystic fibrosis carrier
c. The infant might have cystic fibrosis but more testing is
needed to know for sure
d. Not sure
2. What causes cystic fibrosis?
a. Something that themother did or did not do during pregnancy
b. Having one cystic fibrosis gene that does not work properly
c. Catching it from someone who has cystic fibrosis
d. Having two cystic fibrosis genes that do not work
properly
e. Not sure
3. Which is true about the condition of cystic fibrosis?
a. It is due to the mother's genes only
b. It is due to both the father's and mother's genes
c. It is due to the father's genes only
d. Not sure
4. If a man and a woman are both cystic fibrosis carriers and
they have a child together, what are the chances that the child
could have cystic fibrosis?
a. No chance at all
b. Less than 1 in 100
c. About 1 in 10
d. About 1 in 4
e. About 1 in 2
f. The child will definitely have cystic fibrosis
g. Not sure
5. A man and woman plan to have a child. They get cystic
fibrosis carrier testing. Results show one of them has one
defective cystic fibrosis gene. The testing does not find a defective
cystic fibrosis gene in the other. What are the chances that a future
child of theirs would have cystic fibrosis?a. No chance at all
b. Less than 1 in 100
c. About 1 in 10
d. About 1 in 4
e. About 1 in 2
f. The child will definitely have cystic fibrosis
g. Not sure
Which of the following statements are true, false, or not
sure about being a cystic fibrosis carrier?6. The person has only one cystic fibrosis gene that is not
working properly.True False Not
sure7. A person must have a family history of someone having
the condition of cystic fibrosis to be a carrier.True False Not
sure8. If no defective cystic fibrosis genes are found in carrier
testing, there is still a chance that the person is a carrier.True False Not
sure9. Being a cystic fibrosis carrier will eventually cause illness. True False Not
sure10. Being a cystic fibrosis carrier can cause fertility problems
(difficulty getting pregnant).True False Not
sure11. Although aman and a woman are cystic fibrosis carriers,
they can still have healthy children without cystic fibrosis.True False Not
sure12. If a couple has no relatives with cystic fibrosis, they
cannot have a child with cystic fibrosis.True False Not
sureWhich of the following statements are true, false, or not
sure about parents who have a child who is a cystic fibrosis
carrier and have not yet had carrier testing?13. This infant's brothers and sisters (with the same parents)
could also be cystic fibrosis carriers.True False Not
sure14. These parents could have a child with cystic fibrosis
in the future.True False Not
sureBased on the way autosomal recessive inheritance typically
works, if only one member of a couple is a cystic fibrosis
carrier and the other is not a carrier, which of the following
are true, false, or not sure?15. Future children will always be carriers. True False Not sure
16. Future children could have cystic fibrosis. True False Not sure*Correct answers are in bold.References
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